Immunofluorescence analysis of EpCAM / CD326 was done on 70% confluent log phase HeLa cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with of EpCAM / CD326 (VU-1D9) Mouse Monoclonal Antibody (MA512153) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing cytoplasmic and nuclear localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Small cell lung carcinoma cells|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunohistochemistry (Paraffin) (IHC (P))||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12153 targets Epithelial Specific Antigen in IHC (P) and ICC/IF applications and shows reactivity with Human samples.
The MA5-12153 immunogen is small cell lung carcinoma cells.
EGP40 is a 40kDa transmembrane epithelial glycoprotein, also identified as epithelial specific antigen (ESA), or epithelial cellular adhesion molecule (Ep-CAM). It is expressed on baso-lateral cell surface in most simple epithelia and a vast majority of carcinomas. It reportedly distinguishes adenocarcinomas from pleural mesotheliomas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
MA5-12153 was used in immunocytochemistry to review the current state-of-the-art in circulating tumor cell profiling
|Becker TM,Caixeiro NJ,Lim SH,Tognela A,Kienzle N,Scott KF,Spring KJ,de Souza P||International journal of cancer (134:2523)||2014|
Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition.
MA5-12153 was used in western blot to study TGF-beta1-driven lung cancer cell epithelial-to-mesenchymal transition and the role played by neuropilin-2
|Nasarre P,Gemmill RM,Potiron VA,Roche J,Lu X,Barón AE,Korch C,Garrett-Mayer E,Lagana A,Howe PH,Drabkin HA||Cancer research (73:7111)||2013|
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
MA5-12153 was used in western blot to study the role of ZEB1 in mediating the growth of malignant pleural mesothelioma cells
|Horio M,Sato M,Takeyama Y,Elshazley M,Yamashita R,Hase T,Yoshida K,Usami N,Yokoi K,Sekido Y,Kondo M,Toyokuni S,Gazdar AF,Minna JD,Hasegawa Y||Annals of surgical oncology (19 Suppl 3:S634)||2012|
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
MA5-12153 was used in flow cytometry to study the different molecular phenotype and tumorigenicity of 5 breast cancer cell lines derived from a single patient
|Mosoyan G,Nagi C,Marukian S,Teixeira A,Simonian A,Resnick-Silverman L,DiFeo A,Johnston D,Reynolds SR,Roses DF,Mosoian A||PloS one (8:null)||2013|
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
MA5-12153 was used in immunohistochemistry to identify genes differentially expressed in ovaraian serous adenocarcinoma as compared to healthy ovarian tissue
|Bauerschlag D,Bräutigam K,Moll R,Sehouli J,Mustea A,Salehin D,Krajewska M,Reed JC,Maass N,Hampton GM,Meinhold-Heerlein I||Journal of cancer research and clinical oncology (139:347)||2013|
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
MA5-12153 was used in immunohistochemistry to investigate Lynch syndrome with MSH2-deficient tumors
|Ligtenberg MJ,Kuiper RP,Chan TL,Goossens M,Hebeda KM,Voorendt M,Lee TY,Bodmer D,Hoenselaar E,Hendriks-Cornelissen SJ,Tsui WY,Kong CK,Brunner HG,van Kessel AG,Yuen ST,van Krieken JH,Leung SY,Hoogerbrugge N||Nature genetics (41:112)||2009|
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
MA5-12153 was used in immunohistochemistry to distinguish low malignant potential serous ovarian carcinomas from invasive counterparts
|Meinhold-Heerlein I,Bauerschlag D,Hilpert F,Dimitrov P,Sapinoso LM,Orlowska-Volk M,Bauknecht T,Park TW,Jonat W,Jacobsen A,Sehouli J,Luttges J,Krajewski M,Krajewski S,Reed JC,Arnold N,Hampton GM||Oncogene (24:1053)||2005|
Gene expression patterns in ovarian carcinomas.
MA5-12153 was used in immunohistochemistry to study gene expression patterns in ovarian carcinomas using DNA microarrays
|Schaner ME,Ross DT,Ciaravino G,Sorlie T,Troyanskaya O,Diehn M,Wang YC,Duran GE,Sikic TL,Caldeira S,Skomedal H,Tu IP,Hernandez-Boussard T,Johnson SW,O'Dwyer PJ,Fero MJ,Kristensen GB,Borresen-Dale AL,Hastie T,Tibshirani R,van de Rijn M,Teng NN,Longacre TA,Botstein D,Brown PO,Sikic BI||Molecular biology of the cell (14:4376)||2003|